Fig 5. Neurogenesis is not affected by miR-124 NPs treatment.
(A) Illustration of a coronal slice of the mouse brain representing the areas used to evaluate neurogenesis in the SVZ (red rectangle 1) and the peri-infarct area (red rectangle 2). (B) Representative confocal images of BrdU (green) and DCX (red) staining observed in the SVZ of sham-operated animal, a mouse subjected to PT and saline-treated and a mouse subjected to PT and miR-124 NPs-treated, respectively. Scale bar: 20 μm. Total number of (C, F) doublecortin (DCX)-positive cells, (D, G) BrdU-positive cells and (E, H) DCX/BrdU-double positive cells in the SVZ (C-E) and peri-infarct area (F-H) of mice after sham surgery or PT and indicated treatment conditions. All data are expressed as medians with the 1st and 3rd quartile values, with the following number of animals included in each experimental group: sham n = 11, PT saline n = 6, PT void NPs n = 6, PT scramble-miR NPs n = 8, PT miR-124 NPs n = 8. *p < 0.05 versus sham group and **p < 0.01 versus sham group. Abbreviations: BrdU, 5-bromo-2'-deoxyuridine; NPs, nanoparticles; PT, photothrombosis; SVZ, subventricular zone.